Stimulated intrauterine insemination in women with unilateral tubal occlusion

Gwang Yi, Byung Chul Jee, Chang Suk Suh, Seok Hyun Kim

Objective: To investigate the value of stimulated intrauterine insemination (IUI) in women with unilateral tubal occlusion.

Methods: Superovulation and IUI was performed during 2003-2010 and the medical records were reviewed retrospectively. Thirty-seven infertile women (52 cycles) with unilateral tubal occlusion diagnosed by hysterosalpingography and without other causes of infertility were selected. One-hundred fourteen patients with unexplained infertility served as a control group (182 cycles). The main outcome was the clinical pregnancy rate per cycle.

Results: The pregnancy rate per cycle was similar, 17.3% for the unilateral tubal occlusion group and 16.5% for the unexplained infertility group. The rate of miscarriage (11.1% vs. 23.3%) and ectopic pregnancy (11.1% vs. 6.7%) was similar between the two groups. The pregnancy rate was higher in patients with proximal occlusion (25.0%) compared with distal occlusion (13.9%) or unexplained infertility, but not statistically significant.

Conclusion: Stimulated IUI can be suggested as the initial treatment option in women with unilateral proximal or distal tubal occlusion.

Keywords: Tubal obstruction; Insemination; Pregnancy

Introduction

Tubal pathology is one of the common causes of infertility and is diagnosed in approximately 30% to 35% of infertile women [1]. A history of pelvic inflammatory disease, septic abortion, ruptured appendix, tubal surgery, or ectopic pregnancy strongly suggests the possibility of tubal damage. Most women with tubal factor infertility have detectable chlamydia antibodies suggesting prior infection [2].

The mechanism responsible for tubal factor infertility obviously involves anatomic abnormalities that prevent the union of sperm and ovum. Proximal tubal obstructions prevent sperm from reaching the distal fallopian tube where fertilization normally occurs. Distal tubal occlusions prevent ovum capture from the adjacent ovary. Whereas proximal tubal obstruction is essentially an all-or-none phenomenon, distal tubal occlusive disease exhibits a spectrum ranging from mild (fimbrial agglutination) to moderate (varying degrees of fimbrial phimosis) to severe (complete obstruction).

Hysterosalpingography (HSG) and laparoscopy are the two most common procedures used in the evaluation of mechanical infertility. Images from HSG reveal uterine cavity distortion and the internal architecture of the tubal lumen, neither of which can be evaluated by laparoscopy. Laparoscopy provides detailed information about the pelvic anatomy that HSG cannot, including adhesions, endometriosis, and ovarian pathology. HSG is commonly performed as the first-line approach to assess the anatomy of the uterus and the patency of the fallopian tubes in infertile women [3].
The treatment of patients with patent tubes or with bilateral tubal occlusion diagnosed by HSG is clear. However, there is no single standard management of patients with unilateral tubal occlusion. There may be several treatment options for these patients including superovulation with intrauterine insemination (IUI), in IVF-ET and laparoscopic surgery [4]. However, information available to date on the pregnancy rate after stimulated IUI in patients with HSG findings of unilateral tubal occlusion is scanty. The purpose of this study is to investigate the value of stimulated IUI in women with unilateral tubal occlusion.

Methods

1. Patients

Among the patients who received stimulated IUI during 2003-2010 at the Seoul National University Bundang Hospital, the study group was selected by the following criteria: 1) age ≤ 38-year-old, 2) unilateral tubal occlusion diagnosed by HSG, and 3) without other causes of infertility. Thirty-seven patients met the criteria. The control group consisted of 114 patients with unexplained infertility during the same period and who met the same inclusion criteria, except for normal findings on HSG. Data were collected retrospectively by chart review for selected patients. Cycle outcomes were compared between the study group (52 cycles) and control group (182 cycles). The main outcome parameter was a clinical pregnancy rate per cycle. The Institutional Review Board of our hospital approved the use of the patients’ medical records.

2. Superovulation and IUI

Drugs used for ovarian stimulation included clomiphene citrate (CC) (Clomiphene, Young-Poong, Seoul, Korea), letrozole (Femara, Novartis, Basel, Switzerland), and gonadotropins. Gonadotropins included recombinant FSH (Gonal F, Merck Serono, Geneva, Switzerland), high-purity urinary FSH (Metrodin, Merck Serono), hMG (Menogon, Ferring, Copenhagen, Denmark; Pergonal, Merck Serono; IVF-M, LG life science, Seoul, Korea), or HP-hMG (Menopur, Ferring).

Ovarian stimulation was performed by CC alone (15 cycles), letrozole alone (3 cycles), CC + FSH (55 cycles), CC + hMG (56 cycles), CC + FSH + hMG (38 cycles), letrozole + FSH (10 cycles), letrozole + hMG (24 cycles), letrozole + FSH + hMG (3 cycles), FSH alone (24 cycles), hMG alone (3 cycles), and FSH + hMG (3 cycles). Among them, pituitary suppression was made by GnRH antagonist in 5 cycles and GnRH agonist in 1 cycle. Distribution of the ovarian stimulation regimen was similar between the two groups.

Ovarian stimulation started on the 3rd day of menstruation, after basal ultrasound examination and hormonal assay. Letrozole (2.5 mg/day) or CC (50 to 100 mg/day) was administered for five consecutive days starting from day 3 to 5. The starting dose of gonadotropin was 75 or 150 IU according to the status of the patients, including age, hormonal status, number of cycles, and response in the previous cycle, and was administered every day or every other day from day 3 to 7. Follicular development was monitored by ultrasound and by serum estradiol levels. A single intramuscular injection of 5,000 to 10,000 IU urinary hCG (Profasi, Merck Serono) or 250 μg recombinant hCG (Ovidrel, Merck Serono) was performed if at least one follicle ≥ 18 mm. A single IUI was performed 36 to 40 hours later. If an LH surge was assumed by positive urine LH test on the triggering day, IUI was performed the day after hCG injection. Sperm preparation was performed by the density gradient method (Sperm gradient kits, Cook Medical, Brisbane, Australia). Sperm parameters were recorded as prepreparation values.

A serum β-hCG test was performed 15 to 20 days after hCG administration. In pregnancy cycles, transvaginal ultrasound was performed 4 to 5 weeks after hCG administration. Clinical pregnancy was defined as the presence of a gestational sac on ultrasonography. Miscarriage was defined as the loss of a pregnancy before the 12th week of gestation.

3. Statistical analysis

The SPSS Ver. 17.0 (SPSS Inc., Chicago, IL, USA) was used for data analysis. The Student’s t-test was used for analysis of continuous data and the chi-squared test was used for analysis of categorical data. Differences were considered statistically significant if the p-value < 0.05.

Results

There were no differences in clinical parameters including women’s age, body mass index, and infertility duration between the two groups (Table 1). However, previous history of ectopic pregnancy and abdominopelvic surgery was significantly higher in patients with unilateral tubal occlusion (75 or 150 IU) according to the status of the patients, including age, hormonal status, number of cycles, and response in the previous cycle, and was administered every day or every other day from day 3 to 7. Follicular development was monitored by ultrasound and by serum estradiol levels. A single intramuscular injection of 5,000 to 10,000 IU urinary hCG (Profasi, Merck Serono) or 250 μg recombinant hCG (Ovidrel, Merck Serono) was performed if at least one follicle ≥ 18 mm. A single IUI was performed 36 to 40 hours later. If an LH surge was assumed by positive urine LH test on the triggering day, IUI was performed the day after hCG injection. Sperm preparation was performed by the density gradient method (Sperm gradient kits, Cook Medical, Brisbane, Australia). Sperm parameters were recorded as prepreparation values.

A serum β-hCG test was performed 15 to 20 days after hCG administration. In pregnancy cycles, transvaginal ultrasound was performed 4 to 5 weeks after hCG administration. Clinical pregnancy was defined as the presence of a gestational sac on ultrasonography. Miscarriage was defined as the loss of a pregnancy before the 12th week of gestation.

| Table 1. Patient’s basic clinical characteristics |
|-----------------------------------------------|
| Characteristics | Unilateral tubal occlusion (n = 37) | Unexplained infertility (n = 114) | p-value |
| Patient’s age (yr) | 32.6 ± 3.2 | 32.3 ± 2.9 | NS |
| Husband’s age (yr) | 35.7 ± 4.1 | 36.0 ± 4.1 | NS |
| Body mass index (kg/m²) | 21.9 ± 3.6 | 21.4 ± 2.8 | NS |
| Primary infertility (%) | 51.4 | 67.5 | NS |
| Infertility duration (yr) | 2.8 ± 1.6 | 2.9 ± 1.8 | NS |
| Previous ectopic pregnancy | 6 (16.2) | 4 (3.5) | 0.007 |
| Previous abdominopelvic surgery | 16 (43.2) | 6 (5.3) | < 0.001 |

Values are presented as mean ± standard deviation or number (%). NS, not significant.
lateral tubal occlusion than those with unexplained infertility. Previous ectopic (tubal) pregnancy was treated by salpingectomy in all of the six patients with unilateral tubal occlusion. In the unexplained group, three tubal pregnancies and one cervical pregnancy were noted; the tubal pregnancies were treated by laparoscopic salpingostomy (n = 1), or local (n = 1) or systemic (n = 1) injection of methotrexate. The one cervical pregnancy was treated by cervical curettage. In all of these four patients, the subsequent HSG was normal. Previous abdomino-pelvic surgery included salpingectomy (n = 7), myomectomy (n = 3), oophorectomy (n = 3), ovarian cystectomy (n = 2), cesarean section (n = 1), peritonitis (n = 1), salpingoophorectomy (n = 1), cesarean section+ovarian cystectomy (n = 1), myomectomy+salpingectomy (n = 1), salpingostomy (n = 1), and appendectomy (n = 1).

The number of patients (cycles) with a proximal and distal obstruction was 13 (16) and 24 (36), respectively. There were 5 patients (6 cycles) with hydrosalpinx among the patients with distal tubal occlusion was 13 (16) and 24 (36), respectively. There were 5 patients (6 cycles) with hydrosalpinx among the patients with distal tubal occlusion (n = 52). In the unexplained group, the false positive reading on HSG of proximal tubal occlusion could be a reason for the higher pregnancy rate compared with proximal occlusion (25.0%) or unexplained infertility (16.5%). Therefore, stimulated IUI can be suggested as the initial treatment option in women with unilateral proximal tubal occlusion. Our results also indicate that stimulated IUI can be suggested as the first-line option in women with unilateral distal tubal occlusion because the pregnancy rate was similar to those with unexplained infertility. In another report with a similar design, the cumulative pregnancy rate in women with unilateral mid or distal tubal occlusion (19%) was lower than in those with unilateral proximal tubal occlusion (38.2%) and was significantly lower than in those with unexplained infertility (42.6%) [4]. Thus, in that study the authors concluded that patients with unilateral distal tubal occlusion on HSG should be referred for laparoscopic assessment or IVF. However, we propose that stimulated IUI should be recommended as the first-line option in women with unilateral proximal or distal tubal occlusion.

Proximal occlusion is sometimes just a false reading in which the tube is actually open on subsequent testing. Tubal spasm, temporary mucous plugging, and underfilling of the tube may cause a false-positive by HSG when proximal obstruction is demonstrated. The false-positive rate for proximal tubal obstruction may be as high as 15% [5]. Consequently, confirmation of proximal occlusion by repeat HSG or laparoscopic chromopertubation should be considered. Proximal tubal occlusion can be corrected at the time of initial HSG. In one report, a second HSG yielded bilateral tubal patency in 60% of patients who were diagnosed with proximal tubal obstruction [6]. None of the patients diagnosed with proximal tubal occlusion by HSG in our study group underwent repeat HSG or laparoscopy for confirmation, but it is possible that they might not truly have had tubal occlusion. Therefore, the false positive reading on HSG of proximal tubal occlusion could be a reason for the higher pregnancy rate in our study.

Traditionally, laparoscopy was the final diagnostic procedure of any infertility investigation. However, laparoscopy can be omitted in women with normal HSG or suspected unilateral distal tubal pathology on HSG, since it was not shown to change the original treatment plan indicated by HSG in the majority of the patients. However, lapa-

### Table 2. IUI cycle outcomes

| Clinical parameters                  | Unilateral tubal occlusion (n=52) | Unexplained infertility (n=182) |
|-------------------------------------|----------------------------------|---------------------------------|
| Basal serum LH (mIU/mL)             | 3.6±1.0                          | 4.6±1.7                         |
| Basal serum FSH (mIU/mL)            | 7.0±2.7                          | 6.3±1.8                         |
| Basal serum estradiol (pg/mL)       | 37.8±28.7                        | 28.2±11.1                       |
| Basal serum AMH (ng/mL)             | 4.1±2.4                          | 2.9±1.7                         |
| Semen volume (mL)                   | 3.0±1.6                          | 2.6±1.4                         |
| Sperm concentration (x10⁶/mL)       | 281.3±289.3                      | 261.2±301.8                     |
| Sperm motility (%)                  | 60.3±26.3                        | 57.0±24.1                       |
| Stimulation regimen                 |                                  |                                 |
| CC                                  | 4                                | 11                              |
| Letrozole                            | 0                                | 3                               |
| CC+gonadotropins                    | 41                               | 110                             |
| Letrozole+gonadotropins             | 4                                | 3                               |
| Gonadotropins only                  | 3                                | 27                              |
| Total dose of gonadotropin (IU)     | 445.8±250.7                      | 532.9±328.2                     |
| Number of previous IUI cycles       | 1.83±0.64                        | 1.52±0.78                       |
| Number of follicle (≥16 mm)         | 2.9±1.4                          | 2.8±1.5                         |
| Leading follicle size (mm)          | 20.7±2.2                         | 20.7±2.3                        |
| EM thickness (mm)                   | 8.1±1.8                          | 8.9±2.2                         |
| Clinical pregnancy                  | 9 (17.3)                         | 30 (16.5)                       |
| Clinical abortion                   | 1 (11.1)                         | 7 (23.3)                        |
| Multiple pregnancy                  | 0 (0)                            | 3 (10)                          |
| Ectopic pregnancy                   | 1 (11.1)                         | 2 (6.7)                         |

Values are presented as mean±standard deviation or number (%). All variables are not statistically different between the two groups.

IUI, intrauterine insemination; AMH, anti-Müllerian hormone; CC, clomiphene citrate; EM, endometrial.

at the 7th gestational week. The mean number of follicles was 2.0±1.1 and the mean diameter of the leading follicle was 19.1±2.1 mm in the site of the patent tube at the triggering day. The pregnancy rate was lower in the patients with distal occlusion (13.9%) compared with proximal occlusion (25.0%) or unexplained infertility (16.5%), but was not statistically significant.

## Discussion

In the present study, the pregnancy rate was better in patients with proximal occlusion (25.0%) than in those with distal occlusion (13.9%) or unexplained infertility (16.5%). Therefore, stimulated IUI can be suggested as the initial treatment option in women with unilateral proximal tubal occlusion. Our results also indicate that stimulated IUI can be suggested as the first-line option in women with unilateral distal tubal occlusion because the pregnancy rate was similar to those with unexplained infertility. In another report with a similar design, the cumulative pregnancy rate in women with unilateral mid or distal tubal occlusion (19%) was lower than in those with unilateral proximal tubal occlusion (38.2%) and was significantly lower than in those with unexplained infertility (42.6%) [4]. Thus, in that study the authors concluded that patients with unilateral distal tubal occlusion on HSG should be referred for laparoscopic assessment or IVF. However, we propose that stimulated IUI should be recommended as the first-line option in women with unilateral proximal or distal tubal occlusion.
IUI, all the other treatment options have been investigated in the literature. 

In conclusion, stimulated IUI can be suggested as the initial treatment in women with unilateral proximal or distal tubal occlusion. Because it was a small retrospective study and multiple types of stimulation were lumped together with no differentiation of the various types of stimulation, further prospective randomized studies are needed to verify our findings.

**Conflict of interest**

No potential conflict of interest relevant to this article was reported.

**References**

1. Miller JH, Weinberg RK, Canino NL, Klein NA, Soules MR. The pattern of infertility diagnoses in women of advanced reproductive age. Am J Obstet Gynecol 1999;181:952-7.
2. Veenemans LM, van der Linden PJ. The value of Chlamydia trachomatis antibody testing in predicting tubal factor infertility. Hum Reprod 2002;17:695-8.
3. Balasch J. Investigation of the infertile couple: investigation of the infertile couple in the era of assisted reproductive technology: a time for reappraisal. Hum Reprod 2000;15:2251-7.
4. Farhi J, Ben-Haroush A, Lande Y, Fisch B. Role of treatment with ovarian stimulation and intrauterine insemination in women with unilateral tubal occlusion diagnosed by hysterosalpingography. Fertil Steril 2007;88:396-400.
5. Burney RO. Infertility. In: Bereck JS, Novak E, editors. Berek & Novak’s gynecology. 14th ed. Philadelphia: Lippincott Williams & Wilkins; 2007. p. 1185-275.
6. Dessole S, Meloni GB, Capobianco G, Manzoni MA, Ambrosini G, Canalisi GC. A second hysterosalpingography reduces the use of selective technique for treatment of a proximal tubal obstruction. Fertil Steril 2000;73:1037-9.
7. Lavry Y, Lev-Sagie A, Holzer H, Revel A, Hurwitz A. Should laparoscopy be a mandatory component of the infertility evaluation in infertile women with normal hysterosalpingogram or suspected unilateral distal tubal pathology? Eur J Obstet Gynecol Reprod Biol 2004;114:64-8.
8. Diamond E. A comparison of gross and microsurgical techniques for repair of cornual occlusion in infertility: a retrospective study, 1968-1978. Fertil Steril 1979;32:370-6.
9. Gomel V. An odyssey through the oviduct. Fertil Steril 1983;39:144-56.
10. Lavry G, Diamond MP, DeCherney AH. Pregnancy following tubocornual anastomosis. Fertil Steril 1986;46:21-5.
11. Donnez J, Casanas-Roux F, Nisolle-Pochet M, Waeyenbergh M, Karaman Y. Surgical management of tubal obstruction at the uterotubal junction. Acta Eur Fertil 1987;18:5-9.
12. Honore GM, Holden AE, Schenken RS. Pathophysiology and management of proximal tubal blockage. Fertil Steril 1999;71:785-95.
13. Papaioannou S, Afnan M, Girling AJ, Coomarasamy A, Ola B, Olu-
fowobi O, et al. The effect on pregnancy rates of tubal perfusion pressure reductions achieved by guide-wire tubal catheterization. Hum Reprod 2002;17:2174-9.

14. Marana R, Quagliarello J. Distal tubal occlusion: microsurgery versus in vitro fertilization: a review. Int J Fertil 1988;33:107-15.